Showing results (1-10 of 307) with videos related to
Sort By:
Pageof 31
The Journal of Infectious Diseases|August 4, 2023
Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory DiseasesAxel Finckh, Adrian Ciurea, Catherine E Raptis, et al.Arthritis and Rheumatism|May 2, 2007
Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort studyStéphane Genevay, Axel Finckh, Adrian Ciurea, et al.Joint Bone Spine|May 18, 2010
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patientsAxel Finckh, Jean Dudler, Felix Wermelinger, et al.Arthritis and Rheumatism|May 1, 2009
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisSophie Martin Du Pan, Silvia Dehler, Adrian Ciurea, et al.Rheumatology International|July 30, 2014
Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteriaPascal Zufferey, Jacqueline Ghosn, Fabio Becce, et al.Arthritis and Rheumatism|May 1, 2007
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agentsAxel Finckh, Adrian Ciurea, Laure Brulhart, et al.RMD Open|April 3, 2021
Impact of assessing patient-reported outcomes with mobile apps on patient-provider interactionYomei Shaw, Delphine S Courvoisier, Almut Scherer, et al.Journal of Comparative Effectiveness Research|November 19, 2013
Comparative effectiveness of biologic antirheumatic therapies in rheumatoid arthritis after failure to respond to a first TNF inhibitorAxel FinckhRevue Medicale Suisse|March 13, 2019
[JAK inhibitors in the management of rheumatoid arthritis]Axel FinckhCurrent Rheumatology Reports|July 24, 2010
Comparative effectiveness of rheumatoid arthritis therapiesAxel FinckhPageof 31